Skip to content

Hemab Therapeutics Holdings

US · COAG #3007 by market cap Listed 2026
39.29 -0.57 -1.43%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 39.52 -0.85%
After-hours 39.29 0.00%
54.9424.9839.292026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on COAG?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -18.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 7.1% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Performance

1W -3.84%
1M +14.98%
3M -18.49%
6M +48.43%

Key statistics

Price & volume

Prev close
39.86
Open
39.50
Day range
38.77 - 40.19
Avg price
39.42
Volume
347.02K
Turnover
13.68M
Amplitude
3.56%
52-week range
23.00 - 55.42

Valuation

P/E
-27.17
P/E (TTM)
-19.64
P/B
4.28
EPS
-1.45
Net profit
-67.57M
Net assets
429.27M

Share structure

Market cap
1.84B
Float cap
835.96M
Shares out
46.73M
Float shares
21.28M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2026-05-01
52-week range 50% of range
23.00 55.42

29.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-1.76M net over the window

Short interest

Shares short
3.31M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Hemab Therapeutics Holdings (COAG)?

Hemab Therapeutics Holdings last traded at 39.29. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Hemab Therapeutics Holdings's market cap?

About 1.84B.

What is the P/E ratio of Hemab Therapeutics Holdings?

The trailing twelve-month P/E is -19.64. The Valuation tab shows it against the stock's own five-year range.

Does Hemab Therapeutics Holdings pay a dividend?

Hemab Therapeutics Holdings does not currently pay a regular dividend.

Is Hemab Therapeutics Holdings a buy according to analysts?

The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 64.00, which implies 62.9% upside from the current price. This is not investment advice.

What is Hemab Therapeutics Holdings's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Hemab Therapeutics Holdings a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Hemab Therapeutics Holdings discussion 0 comments

Add a comment